生物信息学和深度学习方法发现食物来源的活性成分,用于阿尔茨海默病治疗
Junyu Zhou1,2, Chen Li2, Yong Kwan Kim3
1Institute of Advanced Clinical Medicine, Peking University, Beijing 100191, China.
Foods (Basel, Switzerland)
|January 11, 2025
概括
这项研究使用生物信息学和深度神经网络来识别来自和黑核桃等食物的166种天然化合物,这些化合物可能有助于预防阿尔茨海默病 (AD). 有希望的化合物在细胞模型中显示出好处,支持对AD的食物衍生干预措施.
科学领域:
- 计算生物学和生物信息学
- 神经科学和衰老研究研究.
- 药理学和药物发现
背景情况:
- 预防阿尔茨海默病 (AD) 是老龄化人口面临的一个重大挑战.
- 来自食物来源的天然化合物 (NC) 是AD的潜在治疗剂.
- 识别有效的NC需要先进的分析方法.
研究的目的:
- 为了确定具有治疗阿尔茨海默病 (AD) 治疗潜力的天然化合物 (NC).
- 为了全面评估,利用与生物信息学集成的深度神经分析方法.
- 用分子对接和体外实验来验证计算预测.
主要方法:
- 在化学数据库上使用生物信息学集成的深度神经分析 (BioDeepNat).
- 使用随机森林回归来预测与AD相关的蛋白质 (AChE, APP, BACE1, MAPT, PSEN1, TNF-α, VCP) 相比的联体IC50值.
- 通过分子对接 (Autodock Vina) 和PC12细胞的体外测试验证实了预测.
主要成果:
- 确定了166种对AD目标具有潜在影响的天然化合物 (NC),显示出高回忆率.
- 最重要的食物来源包括黑核桃,红杉,生,无花果,玉米和胡.
- 高活性化合物 (阿斯特拉加林,二米瑞,氨酸) 和中活性化合物 (卢托林) 改善了细胞存活率,并在体外减少了炎症标志物.
结论:
- 将生物信息学和深度神经网络结合起来,有效地加速了用于AD干预的新型食品衍生NC的发现.
- 该研究确定了特定的NC及其食物来源,这些食物对阿尔茨海默氏症有着有前途的治疗潜力.
- 这些发现支持开发饮食策略和基于天然产品的治疗方法,以预防AD.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.4K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
761
相关概念视频
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
